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Abstract
Background: Childhood obesity is associated with advanced 
bone age (BA). Previous studies suggest that androgens, 
oestrogens, sex hormone-binding globulin, and insulin are 
responsible for this phenomenon, but results are contradic-
tory and might be biased by confounders. We aim to eluci-
date this matter by applying a multivariate approach. Meth-
od: We performed a correlation analysis of BA standard 
deviation score (SDS) with age- and sex-specific SDS for 
androgens, oestrogens, and with indicators of insulin secre-
tion derived from oral glucose tolerance testing, in a group 
of obese children. A multivariate analysis was performed to 
investigate which parameters were independently predic-
tive of BA SDS. Results: In this cohort (n = 101; mean age 10.9 
years; mean BA 11.8 years; mean BMI SDS 3.3), BMI SDS was 
significantly correlated to BA SDS (r = 0.55, p < 0.001). In a 
regression analysis in the total cohort (B = 0.27, p < 0.001) as 
well as in females (B = 0.34, p = 0.042), males (B = 0.31, p = 
0.006), and pubertal children (B = 0.32, p = 0.046), dehydro-
epiandrosterone sulphate (DHEAS) showed a positive, inde-
pendent association with BA SDS. No association with indi-
cators of insulin secretion was found. Conclusion: BMI SDS is 
highly correlated to BA SDS in obese children. Increased 
DHEAS has a central role in advanced BA in obese children.
© 2017 S. Karger AG, Basel
Introduction
The worldwide increase in overweight and obese chil-
dren has led to significant morbidity, including type 2 
diabetes, cardiovascular diseases, fatty liver disease, im-
paired development, and psychological problems [1]. 
Furthermore, children with excess weight have been re-
ported to have accelerated sexual maturation and linear 
growth, often accompanied by an advanced bone age 
(BA) and a decreased pubertal growth spurt compared to 
normal-weight children [2–4]. The mechanism driving 
this BA advancement, however, has remained unclear. 
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Various alterations in hormone levels have been pro-
posed to be responsible for this phenomenon, such as an-
drogens [5–8], oestrogens [5–7, 9], and sex hormone-
binding globulin (SHBG) [7]. Furthermore, 2 recent 
studies indicated that increasing insulin resistance and 
insulin secretion are associated with BA advancement 
[10, 11]. These studies, however, vary widely in study de-
sign and outcome parameters investigated, and led to 
contradictory results. For example, some studies evalu-
ated the difference between BA and chronological age 
(CA) [8, 10], whereas others assessed the ratio between 
these parameters [11], while an age-adjusted indicator 
would theoretically be superior. Furthermore, some stud-
ies included prepubertal children only [6, 10], while oth-
ers also included pubertal children [5, 7]. Additionally, 
most studies reported on androgen and oestrogen levels 
as absolute levels, although these vary significantly with 
age and pubertal staging, making age an important poten-
tial confounder in association studies. Finally, various 
factors are expected to be mutually dependent. 
Therefore, we investigated the multivariate relation-
ship between BA standard deviation score (SDS) for age 
and sex versus age- and sex-adjusted serum concentra-
tions of serum androgens, oestradiol (E2), SHBG (ex-
pressed as SDS), and indicators of insulin secretion in a 
cohort of prepubertal and pubertal obese children. 
Methods
Study Cohort
Obese children visiting our obesity clinic between January 2012 
and July 2015, in whom BA assessment and an oral glucose toler-
ance test (OGTT) were performed, were included in this retrospec-
tive cohort study. The OGTT, BA assessment, and endocrine mea-
surements were, at that time, part of an extensive diagnostic pack-
age which we performed as standard care for all obese children. 
The aims of this diagnostic approach were (a) early detection of 
glucose metabolism abnormalities and other complications of obe-
sity such as polycystic ovary syndrome and (b) detection of endo-
crine or genetic causes of obesity. Exclusion criteria for this study 
were endocrine disorders (e.g., hypothyroidism), syndromes 
known to affect insulin sensitivity or increased skeletal maturation 
BA (e.g., Bardet-Biedl syndrome or overgrowth syndromes), med-
ication affecting insulin sensitivity or skeletal maturation (e.g., 
metformin or methylphenidate), missing fasting insulin or unreli-
able OGTT data (e.g., due to vomiting or problems with i.v. cath-
eter), and missing BA SDS (e.g., outside age reference range of 
BoneXpert). In this cohort, patients with marked hyperphagia and 
early-onset obesity (onset of obesity <5 years of age) were tested 
for genetic causes of obesity by means of a genetic panel developed 
at the University Medical Center in Utrecht. It tests for 53 genes 
known to cause monogenic obesity. Patients with genetic defects 
indicating monogenic obesity were included in this study, since 
there is no reason to assume that their BA is affected in any other 
way than in other obese children. The results for these patients are 
shown with specific symbols in the Figures. The study was ap-
proved by the Medical Ethics Committee of the Leiden University 
Medical Center and conducted within the terms of the Declaration 
of Helsinki. Since all participants received standard of care only, 
subject consent was waived.
Anthropometric Data and Definitions
At the first visit, height and weight were measured using a sta-
diometer and calibrated scale, respectively. Obesity and BMI SDS 
were determined using the International Obesity Taskforce crite-
ria [12]. Height SDS was determined based on the Dutch nation-
wide growth study performed in 2009 [13]. Modified Tanner stag-
ing [14] was performed to determine pubertal stage (Tanner stage 
>G1 in males or >B1 in females were scored as pubertal).
BA Evaluation
We used BoneXpert to determine BA and BA SDS on a radio-
graph of the left hand [15]. BoneXpert is a fully automated system 
based on an extensive database, which determines the Greulich 
and Pyle BA by analyzing 15 bones of the left hand and wrist [15, 
16]. BoneXpert is validated to determine BA and associated SDS 
in males aged 2.5–17 years and in females aged 2–15 years for dif-
ferent ethnicities [15, 16]. We used Caucasian as standard refer-
ence, since our cohort was largely Caucasian and the non-Cauca-
sian participants were of North African and Middle Eastern de-
scent, for which BoneXpert does not provide ethnicity-specific 
SDS. The radiographs were made on the date of the first visit or 
during the visit for OGTT. 
OGTT Procedure
OGTT was performed after an overnight fast with a minimum 
of 10 h. A standardized dose of oral glucose of 1.75 g/kg, with a 
maximum of 75 g, was administered at the beginning of the test. 
An intravenous catheter was used to collect the blood samples at 
t = 0, 30, 60, and 120 min. These samples were analyzed for insulin 
and glucose concentrations. An extra sample to measure concen-
trations of E2, testosterone (T), androstenedione (Adione), dehy-
droepiandrosterone sulphate (DHEAS), and SHBG was obtained 
at t = 0.
Laboratory Measurements
Blood samples were analyzed in the clinical laboratory of the 
Leiden University Medical Center (LUMC, The Netherlands). Im-
mulite 2000 XPi (Siemens Healthcare Diagnostics, Tarrytown, NY, 
USA) immunoassays were used to determine the serum concen-
trations of insulin (mU/L), SHBG (nmol/L), and DHEAS (μmol/L). 
T (nmol/L) was analyzed by immunoassay (ECLIA) on a Roche 
Modular E170 immunoanalyzer, and Adione (nmol/L) was ana-
lyzed using a radioimmunoassay of Beckman Coulter (formerly 
DSL, Woerden, The Netherlands). Glucose was analyzed in serum 
using a hexokinase method on a Roche Modular P800 chemistry 
analyzer. Two different but compatible methods, the automated 
ECLIA assay of Roche and the Orion ultrasensitive radioimmuno-
assay, were used to measure the E2 levels (pmol/L). Concentra-
tions of the Orion radioimmunoassay method were converted to 
ECLIA by a conversion factor. Due to the retrospective nature of 
this study, using data obtained in standard care, no mass spec-
trometry measurements were available for E2 and T. The Roche 
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testosterone (generation 2) and oestradiol (generation 2) assays are 
state-of-the-art immunoassays with limits of detection of 0.09 
nmol/L and 18.4 pmol/L, respectively. Both assays have been stan-
dardized against international reference methods (ID-GCMS). 
The Orion ultrasensitive radioimmunoassay for E2 had a similar 
limit of detection with excellent correlation in comparison with 
the Roche assay.
Concentrations of measured outcomes under the detection 
limit were defined as the mean between the lower detection limit 
of the test and zero. The homeostatic model assessment of insulin 
resistance (HOMA-IR) was calculated using the following formu-
la: T0 glucose (mmol/L) × T0 insulin (mU/L)/22.5 [17]. We calcu-
lated the area under the curve for insulin levels during the OGTT 
using the trapezoid method. 
Conversion of Serum Steroid Levels to SDS
In order to estimate the possible influence of serum SHBG, E2, 
and steroid levels on BA advancement, we converted patients’ se-
rum levels to SDS, based on published reference values using the 
same assays. Since the age distribution is skewed, for each age in-
terval separate SD values were calculated above and below the 
mean. Values for +1 SD and –1 SD were estimated by dividing the 
difference between P97.5 and P50 and the difference between P50 
and P2.5 by 1.96, respectively, as previously described [18]. For 
DHEAS and SHBG we used the age- and sex-specific centiles pro-
vided by Elmlinger et al. [19]. 
Reference data for T and E2 were derived from the Caliper da-
tabase [20]. For these parameters, we calculated SDS only for chil-
dren ≥9.0 years of age, since the reference values for children <9 
years of age were largely below the detection limit. For children 
aged ≥9.0 years with plasma concentrations below the detection 
limit we imputed the data by dividing the lower detection limit by 
2. We used the data from the Caliper database to directly calculate 
1 SDS and –1 SDS in different age groups. 
For DHEAS, SHBG, T, and E2 smoothed-fit lines of the –1 SD, 
P50, and 1 SD data points were created, providing an equation to 
calculate age- and sex-adjusted SDS for these hormones: (serum 
concentration – age-specific P50)/(age-specific –1 or +1 SD); 
SDS(X) = ([X]-P50)/SD. There were no reference data applicable for 
our assay for serum insulin and Adione, so these concentrations in 
our patients could not be expressed as SDS. The results of smooth-
fitting and plots of SDS in our cohort are summarized in the supple-
mentary Figures (SHBG SDS, online suppl. Fig. 1; DHEAS SDS, on-
line suppl. Fig. 2; T SDS, online suppl. Fig. 3; E2 SDS, online suppl. 
Fig. 4; see www.karger.com/doi/10.1159/000467393).
Statistical Analysis
All analyses were performed using IBM 23.0 SPSS Statistics. We 
performed analyses for the total cohort as well as for subgroups based 
on sex and puberty. Normality was tested using the Kolmogorov-
Smirnov and the Shapiro-Wilk tests (p > 0.05 was considered nor-
mally distributed). We report on mean and SD and median with 
interquartile range for Gaussian and non-Gaussian distributed data, 
respectively. For the various SDS we investigated whether they sig-
nificantly differed from zero using one-sample t tests or a one-sam-
ple Kolmogorov-Smirnov test. Correlation analyses were performed 
using Pearson and Spearman correlations depending on normality. 
First, we performed correlation analyses exploring the possible 
effect of age and BMI SDS on the various parameters possibly in-
fluencing BA. We then investigated the correlation of these param-
eters with BA SDS. In both analyses, we report on significant cor-
relations (p < 0.05).
As a last step, we investigated which parameters were indepen-
dently associated with BA SDS using backward regression analyses, 
using the pairwise exclusion option in SPSS. In a model with BA 
SDS as the dependent variable we entered age, sex, DHEAS SDS, 
SHBG SDS, fasting insulin, HOMA-IR, and area under the curve 
for insulin measurements during OGTT and investigated indepen-
dent relationships to BA SDS in the total cohort and subgroups split 
on sex and puberty. E2 SDS and T SDS were only entered in the 
model for the pubertal subgroup, since they were unavailable for 
most prepubertal subjects. We tested the assumptions of each mod-
el by checking the independence of the residuals (Durbin-Watson 
test), inspecting their homogeneity (inspection of the scatterplot), 
and testing their normality (Kolmogorov-Smirnov test >0.05)
Results
Study Cohort Characteristics
Out of the 184 children who visited the Willem-Alex-
ander Children’s Hospital, 101 children met the inclusion 
criteria for this study. Figure 1 summarizes the reasons 
for exclusion of the remaining subjects. 
Visited the clinic
(n = 184)
With BA SDS
(n = 128)
Included in the study
(n = 101)
OGTT data and BA
assessment
(n = 153)
Complete OGTT
data and BA SDS
(n = 109)
31 children excluded due
to being overweight
→ no OGTT
25 children excluded for
missing BA SDS because
age was outside the
reference range of BoneXpert
19 OGTT were partially
missing (e.g., missing fasting
sample) or unreliable
(e.g., vomiting)
5 children excluded for
usage of methylphenidate
1 child excluded for
usage of metformin
1 child excluded for
hypothyroidism
1 child excluded for
overgrowth syndrome
Fig. 1. Flowchart with reasons of exclusion. 
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Baseline characteristics are presented in Table 1. The 
cohort had a mean age of 10.9 years and a mean BA of 
11.8 years, resulting in a mean BA SDS of 1.2; 57% of the 
children were pubertal, and 47% were female. The mean 
height SDS was 0.6 and the mean BMI SDS 3.3. Mean BA 
SDS and DHEAS SDS were increased (both p < 0.001), 
while T SDS and SHBG SDS were decreased compared to 
age references (p = 0.032 and 0.003, respectively). 
In 5 subjects of the final cohort, a genetic mutation 
was found. Two male subjects showed a heterozygous 
Table 1. Baseline characteristics
Total cohort Subgroups by sex Subgroups by puberty
n (n = 101) n female
(n = 47)
n male
(n = 54)
n prepubertal
(n = 43)
n pubertal
(n = 57)
Age, years 101 10.9 (3.1) 47 10.3 (2.9) 54 11.4 (3.1) 43 8.4 (1.9) 57 12.8 (2.3)
BA, years 101 11.8 (2.1) 47 10.9 (2.9) 54 12.6 (2.9) 43 9.6 (2.0) 57 13.5 (2.5)
BA SDS 101 1.2 (1.1)* 47 0.8 (1.2)* 54 1.4 (1.0)* 43 1.6 (1.1)* 57 0.8 (1.1)*
Caucasiana 101 64 (63.4) 47 27 (57.4) 54 37 (68.5) 43 19 (44.2) 57 44 (77.2)
Height SDS 101 0.6 (1.0)* 47 0.4 (1.0)* 54 0.7 (1.1)* 43 0.8 (1.0)* 57 0.4 (1.0)*
BMI SDS 101 3.4 (0.6)* 47 3.1 (0.5)* 54 3.6 (0.7)* 43 3.6 (0.7)* 57 3.2 (0.5)*
Fasting insulin, mU/Lb 101 12 (6/18) 47 11 (6/19) 54 12 (7/16) 43 7 (4/11) 57 16 (10/26)
HOMA-IRb 101 2.1 (1.3/3.7) 47 2.1 (1.3/3.9) 54 2.3 (1.3/3.5) 43 1.3 (0.8/2.0) 57 2.4 (2.1/4.8)
AUC insulin, mU/Lb 94 305 (202/468) 43 267 (186/454) 51 309 (210/482) 40 211 (159/397) 53 362 (238/544)
Oestradiol SDS 50 0.0 (1.4) 21 –0.2 (1.1) 29 0.1 (1.5) – 39 0.0 (1.3)
Testosterone SDSb 64 –0.6 (–1.2/0.3)* 28 –0.7 (–2.7/1.6) 36 –0.6 (–1.1/0.0)* – 51 –0.7 (–1.3/0.4)*
DHEAS SDSb 96 0.4 (0.0/1.0)* 45 0.3 (–0.8/0.7) 51 0.4 (0.1/1.0)* 41 0.4 (–0.3/1.1) 54 0.3 (0.0/0.9)*
SHBG SDSb 96 –1.9 (–2.4/–1.1)* 46 –1.9 (–1.2/–2.2)* 50 –1.9 (–2.4/–1.1)* 40 –1.5 (–2.2/–0.7)* 55 –2.0 (–2.4/–1.4)*
Androstenedione, nmol/Lb 100 2.25 (1.30/3.60) 47 2.40 (1.20/4.10) 53 2.20 (1.30/3.30) 42 1.25 (0.78/2.23) 57 3.00 (2.15/4.50)
Data are expressed as mean (standard deviation) unless otherwise stated. Data on oestradiol SDS and testosterone SDS are on the age group of ≥9 years. 
SDS, standard deviation score; BA, bone age; BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; AUC, area under the 
curve; DHEAS, dehydroepiandrosterone sulphate; SHBG, sex hormone-binding globulin. a n (%). b Median (interquartile range). * SDS, p < 0.05. 
Table 2. Correlations between outcome parameters and age or BMI SDS
BMI SDSa Fasting 
insulin
HOMA-
IR
AUC 
insulin 
Oestradiol 
SDSa
Testosterone 
SDS
DHEAS 
SDS
SHBG 
SDS
Age
Total cohort –0.22* 0.65*** 0.65*** 0.48*** 0.19 –0.17 0.05 –0.12
Female –0.26 0.68*** 0.69*** 0.58*** 0.29 –0.09 0.00 0.02
Male –0.35** 0.63*** 0.62*** 0.40** 0.15 –0.35* 0.03 –0.20
Prepubertal –0.36* 0.59*** 0.61*** 0.53*** – – 0.35* –0.38*
Pubertal 0.28* 0.33* 0.30* 0.24 0.28 –0.10 –0.03 0.19
BMI SDS
Total cohort – –0.08 –0.10 0.11 0.19 0.14 0.20 –0.17
Female – –0.11 0.11 0.06 0.28 0.36 0.22 –0.15
Male – –0.13 –0.15 0.08 0.13 –0.16 0.07 –0.14
Prepubertal – –0.19 –0.25 –0.05 – – 0.13 –0.08
Pubertal – 0.28* 0.28* 0.42** 0.23 0.07 0.27 –0.39**
Correlations are shown as Spearman ρ unless otherwise stated. Correlations for oestradiol SDS and testosterone SDS are calculated 
on the age group of ≥9 years. BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; AUC insulin, area 
under the curve of insulin during oral glucose tolerance test; SDS, standard deviation score; DHEAS, dehydroepiandrosterone sulphate; 
SHBG, sex hormone-binding globulin. a Pearson correlation. * p < 0.05; ** p < 0.01; *** p < 0.001.
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MC4R mutation (Cys293Tyr en Ile251Leu) and 1 male 
subject showed a heterozygous mutation in WDPCP 
(Leu379Ser). Furthermore, 1 female subject showed a 
heterozygous mutation in BBS7 (Gln365Leu), while an-
other female subject was found to have 2 heterozygous 
variants in CEP290 (Ile1059fs) and MKKS (Ala242Ser). 
Correlation between Outcome Parameters and Age or 
BMI SDS
The correlation analysis of the outcome parameters 
with age and BMI SDS are presented in Table 2 and scat-
terplots are shown in Figure 2. The data are presented as 
Pearson correlation or Spearman ρ, where applicable. 
BMI SDS was negatively correlated with age in prepuber-
tal children and positively in pubertal children, showing 
a U-shape over the whole age range (Fig. 2a). 
The insulin parameters in the total cohort as well as in 
subgroups according to sex and puberty showed a posi-
tive correlation with age. T SDS showed a significant neg-
ative correlation with age (ρ = –0.35) in males. In the pre-
pubertal subgroup, SHBG SDS negatively correlated with 
age (ρ = –0.38), in contrast to a positive correlation with 
age (ρ = 0.35) for DHEAS SDS. 
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Fig. 2. a Association between BMI SDS and age (years). b Associa-
tion between BA (BA) (years) and chronological age (years). c As-
sociation between BA SDS and age. d Association between BA SDS 
and BMI SDS. SDS, standard deviation score; BMI, body mass in-
dex; BA, bone age; R2, coefficient of deviation. Squares represent 
males, x’s represent females, circles represent males with monoge-
netic obesity, and asterisks represent females with monogenetic 
obesity.
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Fasting insulin (ρ = 0.28), HOMA-IR (ρ = 0.28), and 
area under the curve for insulin measurements during 
OGTT (ρ = 0.42) showed a significant positive correlation 
with BMI SDS in the pubertal subgroup. BMI SDS showed 
a trend toward a positive correlation with DHEAS SDS in 
the whole cohort and the pubertal subgroup. In contrast, 
there was a trend toward a negative correlation with 
SHBG SDS in the whole cohort, which reached statistical 
significance in the pubertal subgroup. 
Correlation of BA SDS with Clinical and Biochemical 
Parameters 
Figure 2b shows that in the great majority of patients 
BA is advanced. As shown in Table 3 and Figure 2c, BA 
SDS is relatively more advanced in young children: there 
was a significant negative correlation between BA SDS 
and age in the total cohort (r = –0.29) as well as in sub-
groups split on sex (female, r = –0.31; male, r = –0.41). 
BMI SDS showed a strongly significant correlation with 
BA SDS in the total cohort (ρ = 0.55) (Fig. 2d) as well as 
in the female (ρ = 0.49), male (ρ = 0.55), prepubertal (ρ = 
0.52), and pubertal (ρ = 0.51) subgroups. 
Correlations between BA SDS and biochemical vari-
ables are presented in Table 3. In females, T SDS showed 
a positive correlation with BA SDS (ρ = 0.44). In the total 
cohort, as well as in the male and both puberty sub-
groups, DHEAS SDS showed a positive correlation with 
BA SDS. SHBG SDS was negatively associated with BA 
SDS, particularly in pubertal children (ρ = –0.31). The 
insulin parameters and E2 SDS did not show significant 
correlations with BA SDS in the total cohort or in any 
subgroup.
Regression Analysis for BA SDS
The results of backward regression analysis are sum-
marized in Table 4. In the total cohort, backward regres-
sion analysis resulted in a model, including sex, DHEAS 
SDS, and age, explaining 27% of the total variance in BA 
SDS (overall fit of the regression model F = 10.55, p < 
0.001). In the female subgroup we found a model explain-
ing 21% of the variance in BA SDS including DHEAS 
SDS, SHBG SDS, and age (F = 3.33, p = 0.030). In contrast, 
in males the model did not include SHBG SDS, but only 
contained DHEAS SDS and age (F = 9.50, p < 0.001), ex-
plaining 30% of the variance. For the subgroups split on 
puberty, regression analysis showed a model explaining 
31% of the variance in BA SDS, including sex, SHBG SDS, 
and age in prepubertal subjects (F = 4.88, p = 0.006), and 
a model explaining 11% of the variance only including 
DHEAS SDS (F = 4.27, p = 0.046) in pubertal subjects. 
Discussion
The results of this study show that the mechanisms 
driving BA advancement in obese children are complex. 
In multiple regression analyses we have shown that 
DHEAS levels positively associate with BA SDS and 
Table 3. Correlation between BA SDS and clinical and biochemical variables
Total cohort Sex Puberty
female male prepubertal pubertal
Age (years)a –0.29** –0.31* –0.41** –0.15 –0.07
BMI SDSa 0.55*** 0.49*** 0.55*** 0.52*** 0.51***
Fasting insulin –0.14 –0.22 –0.15 0.02 0.09
HOMA-IR –0.14 –0.21 –0.14 –0.03 0.12
AUC insulin 0.07 –0.06 0.13 0.13 0.22
Oestradiol SDSa 0.14 0.13 0.13 – 0.10
Testosterone SDS 0.24 0.44* –0.06 – 0.18
DHEAS SDS 0.29** 0.18 0.33* 0.32* 0.28*
SHBG SDS –0.17 –0.10 –0.22 –0.24 –0.31*
Correlations are expressed as Spearman ρ (p value) unless otherwise stated. Correlations for oestradiol SDS 
and testosterone SDS are calculated on the age group of ≥9 years. SDS, standard deviation score; BA, bone age; 
BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; AUC, area under the 
curve; DHEAS, dehydroepiandrosterone sulphate; SHBG, sex hormone-binding globulin. a Pearson correlation 
(p value). * p < 0.05; ** p < 0.01; *** p < 0.001.
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SHBG levels negatively. However, results are variable 
across subgroups according to sex and pubertal status. 
Furthermore, we were able to explain only a limited per-
centage of the variance in BA SDS (with a maximum of 
31% in prepubertal children), indicating that some fac-
tors driving BA advancement were not included in this 
analysis. 
As expected, in this cohort of obese children, mean 
height SDS was above average for the population, and BA 
was advanced compared to CA. Furthermore, BA SDS 
and BMI SDS were strongly correlated. This is in line with 
studies reporting advanced linear growth and skeletal 
maturation in children with excess weight [2–4, 21]. In 
addition, we have confirmed previous studies [3, 7, 22] 
showing that obese children have high DHEAS levels 
compared to a reference population. Our observation 
that DHEAS SDS is associated with BA SDS, especially in 
pubertal children, independent of various confounders, is 
in accordance with the results of a study by Sopher et al. 
[6], which showed that, in a group of obese children, the 
highest tertile of the ratio between BA and CA was associ-
ated with high DHEAS levels. These authors posed that 
high DHEAS levels indicate high levels of androgens, 
leading to increased levels of E2 by peripheral conversion, 
which in turn leads to advanced bone maturation. The 
absence of an association between E2 and BA SDS in our 
cohort might be caused by the fact that our E2 assay lacks 
sensitivity in the lower ranges. Consistent with this expla-
nation is a study by Klein et al. [9] showing that E2 levels 
correlated with BA in obese and lean children when using 
a more sensitive assay. Alternatively, it has been suggest-
ed that the production of E2 takes place at the tissue level 
[6], so that no rise in circulating E2 levels can be detected, 
thereby explaining the lack of association between E2 and 
BA SDS in our cohort. Furthermore, our findings are in 
line with the work of DeSalvo et al. [23] who showed that, 
in a cohort of children with premature adrenarche, the 
subgroup of children with BA advancement >2 years had 
higher BMI and higher DHEAS levels than the subgroup 
of children with BA advancement <1 year. This might 
suggest an overlap between the pathophysiological mech-
anisms leading to BA advancement in patients with pre-
mature adrenarche and patients with obesity [23]. 
Although the pathophysiological mechanism remains 
uncertain, the results of our study show an independent 
association between DHEAS SDS and BA SDS in the total 
cohort as well as in males, females, and pubertal children, 
indicating a central role for DHEAS in the BA advance-
ment found in obese children. The scientific implications 
of the results of our study are that insulin is an unlikely 
cause of bone advancement in obese children, while 
DHEAS secretion can now be viewed as at least one of the 
intermediary factors. A possible clinical implication of 
our findings could be that it would be useful to measure 
DHEAS in obese children with substantial BA advance-
ment and/or increased statural growth. If available, it 
would also be useful to measure serum E2 with an ultra-
sensitive assay. In case of high concentrations, these could 
be accepted as causes of the clinical phenotype, so that the 
clinician can consider abstaining from further diagnostic 
workup of the patient.
Table 4. Backward regression analysis of BA SDS 
Coefficient 95% CI R2 p
value
Total cohort (n = 88)
Constant 2.17 1.39/2.96 <0.001
Male sex 0.62 0.18/1.06 0.006
DHEAS SDS 0.27 0.09/0.44 <0.001
Age –0.13 –0.20/–0.06 0.036
Model 0.27 <0.001
Female (n = 52)
Constant 2.68 1.25/4.11 0.001
DHEAS SDS 0.34 0.01/0.66 0.042
SHBG SDS 0.29 –0.04/0.62 0.086
Age –0.14 –0.26/–0.02 0.024
Model 0.21 0.030
Male (n = 46)
Constant 2.81 1.80/3.81 <0.001
DHEAS SDS 0.31 0.09/0.52 0.006
Age –0.14 –0.22/–0.05 0.002
Model 0.30 <0.001
Prepubertal (n = 36)
Constant 2.26 1.17/4.02 0.001
Male sex 0.98 0.30/1.67 0.006
SHBG SDS –0.41 –0.76/–0.09 0.013
Age –0.27 –0.46/–0.07 0.009
Model 0.31 0.006
Pubertal (n = 37)
Constant 0.70 0.32/1.08 0.001
DHEAS SDS 0.43 0.01/0.85 0.046
Model 0.11 0.046
Variables included in all models: age, fasting insulin, HOMA-
IR, AUC insulin, DHEAS SDS, SHBG SDS. In the total cohort and 
pubertal subgroups, sex was added as an independent variable. In 
the pubertal subgroup only, oestradiol SDS and testosterone SDS 
were added as independent variables. BA, bone age; HOMA-IR, 
homeostatic model assessment of insulin resistance; SHBG, sex 
hormone-binding globulin; DHEAS, dehydroepiandrosterone sul- 
phate; SDS, standard deviation score.
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Our finding of decreased plasma SHBG levels in obese 
children compared to reference intervals, based on lean 
children, is in accordance with previous reports [3, 7, 23] 
and has been reported to be caused by hyperinsulinaemia, 
related to insulin resistance and low-grade inflammation 
[24]. Using sensitive E2 assays, it was also shown that 
obese adolescents have increased E2 levels, combined 
with decreased SHBG levels, possibly resulting in high 
levels of free E2 [23], which in turn might lead to in-
creased bone maturation [24]. 
In addition to the generally decreased SHBG in obese 
children, we found a negative association in the regres-
sion analysis of SHBG SDS with BA SDS in prepubertal 
children. Decreased SHBG is associated with the increase 
of adrenal androgens during puberty [25], which in turn 
can stimulate bone maturation by locally increasing oes-
trogen levels via expression of aromatase [26]. In con-
trast, a trend toward a positive association between SHBG 
SDS and BA SDS was found in regression analysis in the 
female subgroup, possibly reflecting increased gonadal 
oestrogen production during puberty, stimulating SHBG 
in girls. This association, however, did not reach signifi-
cance (p = 0.086), possibly because it is obscured by a lack 
of assay sensitivity or the combination of the results of 2 
oestrogen immunoassays.
It is of interest that we did not find an association be-
tween any of the insulin parameters with BA advance-
ment, neither in correlation analyses, nor in regression 
analyses. In the literature, contradictory results on the as-
sociation between hyperinsulinaemia and advanced BA 
have been reported. No association between insulin resis-
tance and the ratio between BA and CA was found in pre-
pubertal children in a study by Sopher et al. [6], whereas 
Klein et al. [5] found an association between insulin levels 
and the top tertile of this ratio in a cohort aged 3–18 years. 
Furthermore, Pinhas-Hamiel et al. [11] showed that over-
weight children aged 4–13 years with a fasting insulin >30 
mU/L had a 6.8-fold increased risk of falling into the top 
tertile of the ratio between BA and CA, independent of 
the degree of obesity. Lee et al. [10] investigated the rela-
tion between insulin resistance and BA in prepubertal 
obese children and found an independent, positive cor-
relation between HOMA-IR and the difference between 
BA and CA using multiple regression analysis. None of 
these 3 studies, however, corrected for the possible con-
founding effects of androgens and oestrogens, which 
might bias these results, and the outcome parameter of 
BA advancement was not adjusted for age and gender. 
Furthermore, there was considerable variability in eth-
nicity between studies, which might in part explain the 
differences in outcome. In addition, the positive associa-
tion between insulin secretion and age could lead to bias, 
too. Another possible explanation for the lack of associa-
tion between BA SDS and insulin parameters in this co-
hort might be that a large number of the subjects in this 
cohort is already insulin resistant. Possibly, the effects of 
insulin on BA are more pronounced in children in the 
early stages of developing insulin resistance.
The finding of independent effects of sex in the multi-
ple regression analysis is remarkable. It suggests that male 
and female subjects are differentially affected by increased 
BMI in their advanced bone maturation. This is in agree-
ment with the findings of Crocker et al. [27] who have re-
cently shown that pubertal development is differentially 
affected in obese male and female subjects. They showed 
that, in female subjects, progressive Tanner staging cor-
related with advanced BA, while in boys BA advancement 
was independent of testicular development. Furthermore, 
insulin resistance correlated positively with breast devel-
opment in girls, while it was negatively correlated with 
testicular size in boys [27]. This underlines the sexual di-
morphism in the way obesity affects maturation. 
As shown in our regression models, the maximum 
percentage of variance explained by a model was 31%, 
suggesting that factors not included in this study might 
contribute to BA advancement. It has been suggested that 
leptin [28] and IGF-1 [8] might contribute to BA ad-
vancement in obesity, although recent work by Sopher et 
al. [6] showed no association between these parameters 
and BA advancement. Future studies in larger cohorts 
should include these parameters to clarify the role these 
factors play in this matter.
A major strength of our study is the use of an auto-
mated method for BA assessment, which results in a re-
duced inter-subject and an absent inter-observer variance 
[29]. The use of BoneXpert also enabled the calculation 
of a reliable BA SDS from a representative population ref-
erence. Furthermore, where possible, we used age- and 
sex-specific SDS to investigate the relationship between 
hormone levels and BA SDS, thereby correcting for vari-
ance in these hormones caused by age and sex. Further-
more, we corrected for multiple confounders using re-
gression analysis, which makes a causal relationship be-
tween the observed factors associated with advanced BA 
more plausible. 
A limitation of our study is the fact that BoneXpert 
only supports the BA assessment of boys between 2.5 and 
17 years and girls between 2.0 and 15 years of age [15, 16]. 
However, older adolescents have usually reached near-
adult height by this age, and we pose that therefore they 
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are a clinically less relevant study group. Secondly, Bone-
Xpert contains reference data for SDS of Caucasian, 
Asian, Hispanic, or Afro-Americans [16] but not for chil-
dren of Turkish or Moroccan background. Therefore, we 
used Caucasian references as the standard for all children. 
The majority of the cohort, however, is Caucasian. A 
third limitation is that the assay for E2 has a limited sen-
sitivity, which might obscure its association with BA SDS 
in prepubertal children. Finally, due to the large number 
of potential confounders included in the regression mod-
els, our sample size was too small to investigate sex effects 
separately in the prepubertal and pubertal age group. In 
addition, the small sample size in some subgroups (e.g., 
prepubertal), may have led to false negative results in the 
multiple regression analysis. Future research should 
therefore include larger cohorts, allowing for adjusting 
for multiple confounders in the regression analysis. Fur-
thermore, longitudinal designs could help to gain addi-
tional insights into the mechanisms driving accelerated 
bone maturation in obesity. In addition, future studies 
would benefit from age- and sex-specific SDS for Adione 
and insulin and should include leptin and IGF-1. 
In conclusion, using multiple regression analysis, we 
have shown that increased DHEAS levels, reflecting ad-
renal androgen production, play a central role in BA ad-
vancement in obese children and adolescents and that 
decreased SHBG levels may further contribute to this 
phenomenon, though this finding needs further investi-
gation.
Acknowledgements
We thank Dr. N. van Geloven for advice on the statistical anal-
ysis. The authors express their gratitude to Prof. Dr. H.A. 
Delemarre-van de Waal for her efforts invested in setting up the 
obesity outpatient clinic in the Willem-Alexander Children’s Hos-
pital and for facilitating the set-up of this study. Prof. Delemarre-
van de Waal deceased on February 13, 2014. Furthermore, we 
thank Dr. A. Felius for his support in the clinical part of this study.
Disclosure Statement
There are no conflicts of interest and no sources of funding rel-
evant for this article.
References
 1 Sahoo K, Sahoo B, Choudhury AK, Sofi NY, 
Kumar R, Bhadoria AS: Childhood obesity: 
causes and consequences. J Family Med Prim 
Care 2015;4: 187–192.
 2 de Leonibus C, Marcovecchio ML, Chiavaro-
li V, de Giorgis T, Chiarelli F, Mohn A: Tim-
ing of puberty and physical growth in obese 
children: a longitudinal study in boys and 
girls. Pediatr Obes 2014;9: 292–299.
 3 Denzer C, Weibel A, Muche R, Karges B, Sor-
go W, Wabitsch M: Pubertal development in 
obese children and adolescents. Int J Obes 
2007;31: 1509–1519.
 4 He Q, Karlberg J: Bmi in childhood and its as-
sociation with height gain, timing of puberty, 
and final height. Pediatr Res 2001;49: 244–
251.
 5 Klein KO, Newfield RS, Hassink SG: Bone 
maturation along the spectrum from normal 
weight to obesity: a complex interplay of sex, 
growth factors and weight gain. J Pediatr En-
docrinol Metab 2015;29: 311–318.
 6 Sopher AB, Jean AM, Zwany SK, Winston 
DM, Pomeranz CB, Bell JJ, McMahon DJ, 
Hassoun A, Fennoy I, Oberfield SE: Bone age 
advancement in prepubertal children with 
obesity and premature adrenarche: possible 
potentiating factors. Obesity 2011;19: 1259–
1264.
 7 Vandewalle S, Taes Y, Fiers T, Van Helvoirt 
M, Debode P, Herregods N, Ernst C, van Cae-
negem E, Roggen I, Verhelle F, De Schepper 
J, Kaufman JM: Sex steroids in relation to sex-
ual and skeletal maturation in obese male ad-
olescents. J Clin Endocrinol Metab 2014;99: 
2977–2985.
 8 Reinehr T, de Sousa G, Wabitsch M: Relation-
ships of IGF-I and androgens to skeletal mat-
uration in obese children and adolescents. 
J Pediatr Endocrinol Metab 2006;19: 1133–
1140.
 9 Klein KO, Larmore KA, de Lancey E, Brown 
JM, Considine RV, Hassink SG: Effect of obe-
sity on estradiol level, and its relationship to 
leptin, bone maturation, and bone mineral 
density in children. J Clin Endocrinol Metab 
1998;83: 3469–3475.
10 Lee HS, Shim YS, Jeong HR, Kwon EB, Hwang 
JS: The Association between bone age ad-
vancement and insulin resistance in prepu-
bertal obese children. Exp Clin Endocrinol 
Diabetes 2015;123: 604–607.
11 Pinhas-Hamiel O, Benary D, Mazor-Aronov-
ich K, Ben-Ami M, Levy-Shraga Y, Boyko V, 
Modan-Moses D, Lerner-Geva L: Advanced 
bone age and hyperinsulinemia in overweight 
and obese children. Endocr Pract 2014;20: 
62–67.
12 Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: 
Establishing a standard definition for child 
overweight and obesity worldwide: interna-
tional survey. BMJ 2000;320: 1240–1243.
13 Schonbeck Y, Talma H, van Dommelen P, 
Bakker B, Buitendijk SE, HiraSing RA, van 
Buuren S: Increase in prevalence of over-
weight in Dutch children and adolescents: a 
comparison of nationwide growth studies in 
1980, 1997 and 2009. PLoS One 2011;6:e27608.
14 Tanner JM: Growth and maturation during 
adolescence. Nutr Rev 1981;39: 43–55.
15 Thodberg HH, Kreiborg S, Juul A, Pedersen 
KD: The BoneXpert method for automated 
determination of skeletal maturity. IEEE 
Trans Med Imaging 2009;28: 52–66.
16 Thodberg HH, Savendahl L: Validation and 
reference values of automated bone age deter-
mination for four ethnicities. Acad Radiol 
2010;17: 1425–1432.
17 Matthews DR, Hosker JP, Rudenski AS, Nay-
lor BA, Treacher DF, Turner RC: Homeosta-
sis model assessment: insulin resistance and 
beta-cell function from fasting plasma glu-
cose and insulin concentrations in man. Dia-
betologia 1985;28: 412–419.
18 Gerver WJM, de Bruin R: Paediatric Morpho-
metrics, ed 2. Groningen, Wetenschappelijke 
uitgeverij Bunge, 2001.
Childhood Obesity and Bone Age 
Advancement
263Horm Res Paediatr 2017;87:254–263
DOI: 10.1159/000467393
19 Elmlinger MW, Kuhnel W, Ranke MB: Refer-
ence ranges for serum concentrations of lu-
tropin (LH), follitropin (FSH), estradiol (E2), 
prolactin, progesterone, sex hormone-bind-
ing globulin (SHBG), dehydroepiandros-
terone sulfate (DHEAS), cortisol and ferritin 
in neonates, children and young adults. Clin 
Chem Lab Med 2002;40: 1151–1160.
20 Konforte D, Shea JL, Kyriakopoulou L, Col-
antonio D, Cohen AH, Shaw J, Bailey D, Chan 
MK, Armbruster D, Adeli K: Complex bio-
logical pattern of fertility hormones in chil-
dren and adolescents: a study of healthy chil-
dren from the CALIPER cohort and establish-
ment of pediatric reference intervals. Clin 
Chem 2013;59: 1215–1227.
21 Quattrin T, Liu E, Shaw N, Shine B, Chiang E: 
Obese children who are referred to the pedi-
atric endocrinologist: characteristics and out-
come. Pediatrics 2005;115: 348–351.
22 l’Allemand D, Schmidt S, Rousson V, Brabant 
G, Gasser T, Gruters A: Associations between 
body mass, leptin, IGF-I and circulating adre-
nal androgens in children with obesity and 
premature adrenarche. Eur J Endocrinol 
2002;146: 537–543.
23 DeSalvo DJ, Mehra R, Vaidyanathan P, 
Kaplowitz PB: In children with premature ad-
renarche, bone age advancement by 2 or more 
years is common and generally benign. J Pe-
diatr Endocrinol Metab 2013;26: 215–221.
24 Vandewalle S, Taes Y, van Helvoirt M, De-
bode P, Herregods N, Ernst C, Roef G, van 
Caenegem E, Roggen I, Verhelle F, Kaufman 
JM, de Schepper J: Bone size and bone 
strength are increased in obese male adoles-
cents. J Clin Endocrinol Metab 2013;98: 3019–
3028.
25 Garces C, Oya I, Lasuncion MA, Lopez-Si-
mon L, Cano B, de Oya M: Sex hormone-
binding globulin and lipid profile in pubertal 
children. Metabolism 2010;59: 166–171.
26 Oz OK, Millsaps R, Welch R, Birch J, Zerwekh 
JE: Expression of aromatase in the human 
growth plate. J Mol Endocrinol 2001;27: 249–
253.
27 Crocker MK, Stern EA, Sedaka NM, Shomak-
er LB, Brady SM, Ali AH, Shawker TH, Hub-
bard VS, Yanovski JA: Sexual dimorphisms in 
the associations of BMI and body fat with in-
dices of pubertal development in girls and 
boys. J Clin Endocrinol Metab 2014;99:E1519–
E1529.
28 Maor G, Silbermann M, von der Mark K, 
Heingard D, Laron Z: Insulin enhances the 
growth of cartilage in organ and tissue cul-
tures of mouse neonatal mandibular condyle. 
Calcif Tissue Int 1993;52: 291–299.
29 Martin DD, Wit JM, Hochberg Z, Savendahl 
L, van Rijn RR, Fricke O, Cameron N, Caliebe 
J, Hertel T, Kiepe D, Albertsson-Wikland K, 
Thodberg HH, Binder G, Ranke MB: The use 
of bone age in clinical practice – part 1. Horm 
Res Paediatr 2011; 76: 1–9.
